Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Deal Watch: Lilly Teams Up With Lycia In Protein Degradation
Lilly hopes to address immunology and pain indications with biotech’s LYTAC technology. Sunovion licenses European rights to Parkinson’s therapy Kynmobi to Bial.
More from Deal Watch
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.
• By
Vertex, Sanofi, Hansoh and BMS/Myokardia have also recently exited deals. Callio launched with ADC technology from Hummingbird, plus more deals and tech transfer.
More from Deals
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
• By
UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.